Marissa Nichole Rylander1, Yusheng Feng, Jon Bass, Kenneth R Diller. 1. Department of Mechanical Engineering and School of Biomedical Engineering and Sciences, Virginia Tech Corporate Research Center Building XV MC 0493, 1880 Pratt Drive, Blacksburg, Virginia 24061, USA. mnr@vt.edu
Abstract
BACKGROUND AND OBJECTIVES: Hyperthermia can induce heat shock protein (HSP) expression in tumor regions where non-lethal temperature elevation occurs, enhancing cell viability and resistance to chemotherapy and radiation treatments typically employed in conjunction with thermal therapy. However, HSP expression control has not been incorporated into current thermal therapy design. Treatment planning models based on achieving the desired post-therapy HSP expression and injury distribution in the tumor and healthy surrounding tissue can enable design of more effective thermal therapies that maximize tumor destruction and minimize healthy tissue injury. STUDY DESIGN/ MATERIALS AND METHODS: An optimization algorithm for prostate cancer laser therapy design was integrated into a previously developed treatment planning model, permitting prediction and optimization of the spatial and temporal temperature, HSP expression, and injury distributions in the prostate. This optimization method is based on dosimetry guidelines developed from measured HSP expression kinetics and injury data for normal and cancerous prostate cells and tumors exposed to hyperthermia. RESULTS: The optimization model determines laser parameters (wavelength, power, pulse duration, fiber position, and number of fibers) necessary to satisfy prescribed HSP expression and injury distributions in tumor and healthy tissue. Optimization based on achieving desired injury and HSP expression distributions within the tumor and normal tissue permits more effective tumor destruction and diminished injury to healthy tissue compared to temperature driven optimization strategies. CONCLUSIONS: Utilization of the treatment planning optimization model can permit more effective tumor destruction by mitigating tumor recurrence and resistance to chemotherapy and radiation arising from HSP expression and insufficient injury. 2007 Wiley-Liss, Inc
BACKGROUND AND OBJECTIVES:Hyperthermia can induce heat shock protein (HSP) expression in tumor regions where non-lethal temperature elevation occurs, enhancing cell viability and resistance to chemotherapy and radiation treatments typically employed in conjunction with thermal therapy. However, HSP expression control has not been incorporated into current thermal therapy design. Treatment planning models based on achieving the desired post-therapy HSP expression and injury distribution in the tumor and healthy surrounding tissue can enable design of more effective thermal therapies that maximize tumor destruction and minimize healthy tissue injury. STUDY DESIGN/ MATERIALS AND METHODS: An optimization algorithm for prostate cancer laser therapy design was integrated into a previously developed treatment planning model, permitting prediction and optimization of the spatial and temporal temperature, HSP expression, and injury distributions in the prostate. This optimization method is based on dosimetry guidelines developed from measured HSP expression kinetics and injury data for normal and cancerous prostate cells and tumors exposed to hyperthermia. RESULTS: The optimization model determines laser parameters (wavelength, power, pulse duration, fiber position, and number of fibers) necessary to satisfy prescribed HSP expression and injury distributions in tumor and healthy tissue. Optimization based on achieving desired injury and HSP expression distributions within the tumor and normal tissue permits more effective tumor destruction and diminished injury to healthy tissue compared to temperature driven optimization strategies. CONCLUSIONS: Utilization of the treatment planning optimization model can permit more effective tumor destruction by mitigating tumor recurrence and resistance to chemotherapy and radiation arising from HSP expression and insufficient injury. 2007 Wiley-Liss, Inc
Authors: Jessica W Fisher; Saugata Sarkar; Cara F Buchanan; Christopher S Szot; Jon Whitney; Heather C Hatcher; Suzy V Torti; Christopher G Rylander; Marissa Nichole Rylander Journal: Cancer Res Date: 2010-11-23 Impact factor: 12.701
Authors: Feifan Zhou; Xiaosong Li; Mark F Naylor; Tomas Hode; Robert E Nordquist; Luciano Alleruzzo; Joseph Raker; Samuel S K Lam; Nan Du; Lei Shi; Xiuli Wang; Wei R Chen Journal: Cancer Lett Date: 2015-01-26 Impact factor: 8.679
Authors: Yusheng Feng; David Fuentes; Andrea Hawkins; Jon M Bass; Marissa Nichole Rylander Journal: Comput Methods Appl Mech Eng Date: 2009 Impact factor: 6.756
Authors: Kelvin Le; Xiaosong Li; Daniel Figueroa; Rheal A Towner; Philippe Garteiser; Debra Saunders; Nataliya Smith; Hong Liu; Tomas Hode; Robert E Nordquist; Wei R Chen Journal: J Biomed Opt Date: 2011-12 Impact factor: 3.170